HEALTH-RELATED QUALITY OF LIFE IN KERATINOCYTE CARCINOMA PATIENTS

A. Meertens[1,2,3], L. Van Coile[1,2], A. Shen[1,2], K. Vossaert[4], R. Waalboer-Spuij[5], L. Van Wilder[3], L. Brochez[1,2], N. Verhaeghe[3], I. Hoorens[1,2] 1. Department of Dermatology, University Hospital Ghent, Ghent Belgium. 2. Cancer Research Institute Ghent (CRIG), Ghent Belgium. 3. Department of Public Health and Primary Care, Ghent University, Belgium. 4. Private Dermatology Practice, Maldegem, Belgium. 5. Department of Dermatology, Erasmus Medical Center, Rotterdam, the Netherlands

INTRODUCTION

- **Keratinocyte carcinoma (KC),** encompassing BCC and SCC, **constitutes 90% of all skin cancers.**
- KC is less aggressive than melanoma but may impact patients' **health-related quality of life** (HRQoL).
- Studies examining **the impact of KC on HRQoL** are limited and often rely on the use of invalid generic measurement instruments.

SCC BCC MSC

OBJECTIVE

To measure the impact of KC on HRQoL **using generic measurement instruments and a disease-specific questionnaire,** while comparing these in a multicenter cross-sectional study.

METHODS

Study population
Patients (≥18 years) diagnosed with KC <10 years ago were included in Ghent, Maldegem or Rotterdam.

Data collection
Clinical data collected through patient files.
HRQoL data through questionnaires:

- **Disease-specific questionnaire:** Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) questionnnaire.
- **Generic instruments:** EQ-5D-5L, VAS, TTO and 15-D

Questionnaire scores were stratified by KC group
- **Single KC:** Patients with 1 tumor lesion
- **Multiple KC:** Patients with multiple tumor lesions

Statistical analyses
Generalized linear models assessed differences in mean HRQoL scores adjusting for:
- Inclusion center
- Age
- Sex
- Tumor location
- Treatment
- Comorbidities
- Time between diagnosis and survey

Significance level was set at $p<.005$

RESULTS

♂ **n=377**

♀ **n=338**

Study characteristics

Total study population
715 KC patients

332 Single KC
383 Multiple KC

Mean age
66.4 years

Location of tumor
Facial (62%, non-facial (38%)

Most common treatment
Standard exision (40%) and Mohs (35%)

BaSQoL questionnaire scores

Behavior
- Single KC: 0,86
- Multiple KC: 0,88

Diagnosis & Treatment
- Single KC: 1,06
- Multiple KC: 1,07

Worries
- Single KC: 0,87 *
- Multiple KC: 1,03

Appearance
- Single KC: 0,44
- Multiple KC: 0,52

Other people
- Single KC: 1,16
- Multiple KC: 1,27

BaSQoL scores range from 0 to 3, with 0 incidating no impact on HRQoL and 3 indicating high impact.

Generic instruments

EQ-5D-5L utility
- Single KC: 0,9
- Multiple KC: 0,85 *

VAS utility
- Single KC: 0,75
- Multiple KC: 0,71

TTO utility
- Single KC: 0,93
- Multiple KC: 0,94

15D utility
- Single KC: 0,91
- Multiple KC: 0,89

Utility scores range from 0 to 1, with 0 incidating death and 1 indicating perfect health state. ***p<.005**

CONCLUSION

Findings suggest, both with disease-specific and generic measurement instruments, **a minimal impact of KC on HRQoL.** However, patients with multiple KC experienced a higher impact on HRQoL in subdomain worries and a worser health state measured with the EQ-5D-5L. Results need to be interpreted with caution due to the cross-sectional nature of this study.

UZ GENT GHENT UNIVERSITY FACULTY OF MEDICINE AND HEALTH SCIENCES

BDD 2023 poster 18

annick.meertens@uzgent.be
isabelle.hoorens@uzgent.be